Such findings uncover a previously unknown mechanism through which cancer CD39 instructs T cell differentiation and function in NSCLC patients, which are valuable to optimize therapeutics that incorporate CD39-targeting strategy for cancer therapy. This evidence concerns the gene ENTPD1 and non-small cell lung carcinoma.